Premium
The outcome of post‐transplant transitional cell carcinoma in 10 renal transplant recipients
Author(s) -
Wang HwaBen,
Hsieh HweiHo,
Chen YenTa,
Chiang ChaoYang,
Cheng YuanTso
Publication year - 2002
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2002.01152.x
Subject(s) - medicine , transitional cell carcinoma , urology , epirubicin , cystectomy , chemotherapy , transplantation , urinary system , surgery , hemodialysis , bladder cancer , cancer , cyclophosphamide
At our clinic we followed 320 renal transplant recipients, 16 of whom developed malignancies within 15 yr. Ten of the 16 malignancies were transitional cell carcinoma (TCC) of the urinary tract. The modalities of treatment included standard nephroureterectomy with bladder cuff removal for upper tract tumor, transurethral resection for superficial bladder tumor and partial cystectomy for one case of invasive bladder tumor, as requested by the patient. Post‐operative intravesical chemotherapy with epirubicin, or immunotherapy with bacillus Calmette–Guerin (BCG) were carried out for superficial bladder tumor. Cyclosporine (CsA) used as post‐transplant immunosuppressant was switched to low dose azathioprine (Aza) at the initial diagnosis of TCC. Four patients experienced tumor recurrence despite conversion of immunosuppressant from CsA to Aza. Among these 10 patients, five maintained normal renal function, three returned to hemodialysis without tumor recurrence, and two patients died of cancer.